Cardiol Therapeutics Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
CRDL Nasdaq 2834 www.cardiolrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Cardiol Therapeutics Inc.

Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders - May 29th, 2025 5:27 am
Cardiol Therapeutics to Webcast Virtual Annual General Meeting of Shareholders on May 28th at 4:30 p.m. EDT - May 27th, 2025 5:27 am
Cardiol Therapeutics Nominates Dr. Timothy Garnett to Its Board of Directors - Apr 29th, 2025 5:27 am
Cardiol Therapeutics Enrolls First Patient in Pivotal Phase III MAVERIC Trial in Recurrent Pericarditis - Apr 16th, 2025 5:27 am
We're Keeping An Eye On Cardiol Therapeutics' (TSE:CRDL) Cash Burn Rate - Apr 2nd, 2025 6:26 am
Cardiol Therapeutics Announces Year-End 2024 Update on Operations - Apr 1st, 2025 5:27 am
Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference - Mar 3rd, 2025 5:27 am
Cardiol Therapeutics Announces Publication of Research in the Journal of the American College of Cardiology: Basic to Translational Science That Supports Development of Its Proprietary Subcutaneous Drug Candidate, CRD-38, for the Treatment of Heart Failure - Feb 20th, 2025 5:27 am
Cardiol Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference - Feb 4th, 2025 5:27 am
PRISM MarketView Features Q&A with President and CEO David Elsley: Cardiol Therapeutics Enters Phase 3 Clinical Trial for CardiolRx™ Addressing Patients with Recurrent Pericarditis - Dec 19th, 2024 6:30 am
Cardiol Therapeutics' Phase II MAvERIC-Pilot Clinical Results in Recurrent Pericarditis Presented at the American Heart Association Scientific Sessions 2024 - Nov 18th, 2024 9:37 am
Cardiol Therapeutics Inc. Added to PRISM Emerging Biotech Index - Nov 13th, 2024 6:00 am
Cardiol Therapeutics to Advance CardiolRx(TM) into a Late-Stage Trial in Patients with Recurrent Pericarditis - Oct 22nd, 2024 4:30 am
Cardiol Therapeutics Announces Exercise and Closing of Over-Allotment Option - Oct 11th, 2024 6:39 am
Cardiol Therapeutics Announces Closing of US$13.5 Million Public Offering of Common Shares - Oct 10th, 2024 7:09 am
Cardiol Therapeutics Announces Pricing of Public Offering of Common Shares - Oct 9th, 2024 5:58 am
Cardiol Therapeutics Files Preliminary Prospectus Supplement for Proposed Public Offering of Common Shares - Oct 8th, 2024 2:01 pm
Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis - Sep 24th, 2024 5:27 am
Cardiol Therapeutics Announces Completion of the MAvERIC Phase II Study in Recurrent Pericarditis with Results to be Presented at the American Heart Association Scientific Sessions 2024 - Sep 10th, 2024 5:27 am